Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
161 shown of 2,682 total abstracts
  1. Abstract 18692026-09-02 · 18:30 CT · E450
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    G. Curigliano, M. Reck · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  2. Abstract 10982026-09-02 · 16:00 CT · S100A
    Long-term follow-up of Keytruda 2L for TNBC: KEYNOTE-114
    G. Curigliano, S. Peters · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  3. Abstract 19072026-09-03 · 20:30 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-234
    M. Reck, R. Herbst, E. Winer, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  4. Abstract 11992026-09-02 · 15:15 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 1L for HR+ breast cancer: OlympiA-545
    E. Winer, C. Robert · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  5. Abstract 15862026-09-03 · 15:00 CT · Hall B1
    MONARCH-725: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    C. Saura, L. Paz-Ares, H. Borghaei, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  6. Abstract 19612026-09-05 · 16:00 CT · Arie Crown Theater
    MONARCH-21: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    F. Andre, L. Paz-Ares · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  7. Abstract 17062026-09-04 · 21:15 CT · Hall B1
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    G. Curigliano, F. Andre · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  8. Abstract 17522026-09-05 · 14:15 CT · S100A
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    C. Robert, S. Tolaney, M.C. Garassino, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  9. Abstract 10482026-09-02 · 16:45 CT · E450
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-16 study)
    J. Cortes, J. Brahmer, C. Robert · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  10. Abstract 11742026-09-01 · 18:45 CT · Hall B1
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    S. Modi, C. Saura, N. Rizvi, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  11. Abstract 17972026-09-05 · 16:30 CT · S100A
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-618
    H. Rugo, C. Robert, J. Cortes, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  12. Abstract 13562026-09-04 · 18:00 CT · S406
    PALOMA-980: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    F. Andre, C. Saura, H. Borghaei · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  13. Abstract 10422026-09-02 · 18:45 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-290
    S. Antonia, P. Schmid · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  14. Abstract 17482026-09-04 · 16:15 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 2L for TNBC: KEYNOTE-123
    T. Mok, F. Andre, S. Tolaney · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  15. Abstract 14872026-09-03 · 18:00 CT · S100A
    PALOMA-513: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    F. Andre, S. Antonia · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  16. Abstract 10762026-09-01 · 15:15 CT · E450
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    R. Herbst, S. Peters, J. Brahmer · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  17. Abstract 13722026-09-02 · 16:45 CT · S100A
    MONARCH-245: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    H. Borghaei, E. Winer, S. Antonia, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  18. Abstract 19442026-09-01 · 14:00 CT · E450
    PALOMA-116: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    A. Spira, M.C. Garassino · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  19. Abstract 12232026-09-02 · 16:00 CT · S100A
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    S. Peters, S. Antonia, P. Schmid, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  20. Abstract 16822026-09-04 · 13:30 CT · S100A
    MONARCH-159: Verzenio (abemaciclib) 2L in HR+ breast cancer
    F. Andre, C. Saura, R. Herbst, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  21. Abstract 13012026-09-02 · 21:15 CT · S100A
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-413
    J. Cortes, M.C. Garassino · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  22. Abstract 13182026-09-01 · 21:45 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-747
    J. Brahmer, E. Winer, S. Modi, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  23. Abstract 10792026-09-05 · 14:00 CT · S406
    OlympiA-754: Lynparza (olaparib) maintenance in HR+ breast cancer
    A. Spira, R. Herbst, J. Brahmer, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  24. Abstract 10122026-09-01 · 14:00 CT · S406
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-280
    J. Brahmer, P. Schmid, N. Rizvi, et al. · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  25. Abstract 17592026-09-03 · 14:15 CT · S100A
    KEYNOTE-965: Keytruda (pembrolizumab) maintenance in TNBC
    E. Winer, H. Borghaei · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  26. Abstract 18132026-09-02 · 14:45 CT · Arie Crown Theater
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-505
    J. Cortes, M.C. Garassino, C. Robert, et al. · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  27. Abstract 17422026-09-02 · 18:30 CT · S406
    MONALEESA-395: Kisqali (ribociclib) maintenance in HR+ breast cancer
    M. Reck, F. Andre, S. Tolaney, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  28. Abstract 19412026-09-03 · 20:15 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-291 study)
    E. Winer, S. Peters · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  29. Abstract 10642026-09-04 · 21:30 CT · S100A
    Long-term follow-up of Trodelvy maintenance for TNBC: ASCENT-735
    M. Reck, F. Andre, M. Krop · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  30. Abstract 14602026-09-03 · 18:45 CT · S100A
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-541
    F. Andre, R. Herbst, M. Krop, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  31. Abstract 11412026-09-05 · 20:30 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-51
    C. Saura, S. Antonia · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  32. Abstract 16552026-09-02 · 18:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-843 study)
    F. Andre, M. Reck, S. Tolaney · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  33. Abstract 12052026-09-03 · 18:30 CT · S100A
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    N. Rizvi, M.C. Garassino, C. Robert, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  34. Abstract 11542026-09-03 · 15:45 CT · Hall B1
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    S. Antonia, H. Rugo, G. Curigliano, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  35. Abstract 14102026-09-03 · 21:00 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-702
    S. Antonia, C. Saura · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  36. Abstract 19292026-09-03 · 16:45 CT · Hall B1
    MONARCH-916: Verzenio (abemaciclib) 1L in HR+ breast cancer
    H. Rugo, R. Herbst, F. Andre, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  37. Abstract 11402026-09-05 · 16:00 CT · Hall B1
    Quality of life outcomes with Trodelvy in patients with TNBC
    J. Brahmer, H. Borghaei, C. Saura, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  38. Abstract 15972026-09-01 · 18:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-570 study)
    T. Mok, H. Borghaei, P. Schmid, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  39. Abstract 19552026-09-01 · 16:45 CT · Arie Crown Theater
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-492
    S. Modi, L. Paz-Ares, F. Andre · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  40. Abstract 11222026-09-05 · 19:15 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-649
    H. Rugo, R. Herbst · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  41. Abstract 15062026-09-03 · 20:30 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-276
    P. Schmid, A. Spira, N. Rizvi · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  42. Abstract 13192026-09-02 · 21:30 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-197
    S. Tolaney, R. Herbst · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  43. Abstract 11792026-09-05 · 13:15 CT · E450
    Quality of life outcomes with Keytruda in patients with TNBC
    C. Robert, M. Reck, T. Mok, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  44. Abstract 17312026-09-05 · 21:15 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-53
    A. Spira, S. Peters · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  45. Abstract 18452026-09-03 · 19:00 CT · Hall B1
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-987
    M.C. Garassino, S. Modi · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  46. Abstract 14152026-09-02 · 15:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-679 study)
    T. Mok, F. Andre, R. Herbst, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  47. Abstract 13882026-09-04 · 15:45 CT · S406
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-464
    G. Curigliano, N. Rizvi · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  48. Abstract 10002026-09-02 · 13:15 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-67
    L. Paz-Ares, C. Robert, P. Schmid, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  49. Abstract 19352026-09-02 · 18:45 CT · Hall B1
    Long-term follow-up of Enhertu 1L for HR+ breast cancer: DESTINY-Breast-932
    R. Herbst, H. Borghaei, C. Saura · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  50. Abstract 17952026-09-05 · 18:15 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-474
    S. Peters, P. Schmid · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  51. Abstract 10412026-09-04 · 20:15 CT · E450
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-985
    L. Paz-Ares, P. Schmid, M. Krop · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  52. Abstract 16432026-09-02 · 16:00 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-408
    G. Curigliano, L. Paz-Ares, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  53. Abstract 16892026-09-02 · 21:15 CT · S100A
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    E. Winer, N. Rizvi, T. Mok, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  54. Abstract 18882026-09-01 · 15:45 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-414 study)
    T. Mok, C. Saura · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  55. Abstract 16342026-09-04 · 21:30 CT · E450
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-134
    P. Schmid, E. Winer · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  56. Abstract 10252026-09-03 · 16:00 CT · S406
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-449
    E. Winer, L. Paz-Ares, F. Andre, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  57. Abstract 11152026-09-04 · 19:00 CT · S406
    OlympiA-126: Lynparza (olaparib) adjuvant in HR+ breast cancer
    F. Andre, J. Cortes, N. Rizvi, et al. · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  58. Abstract 18162026-09-01 · 19:45 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-887
    S. Tolaney, S. Modi, M. Reck · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  59. Abstract 10212026-09-02 · 19:30 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-176
    J. Brahmer, N. Rizvi, A. Spira · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  60. Abstract 11022026-09-05 · 18:30 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-577
    E. Winer, R. Herbst, C. Robert, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  61. Abstract 14922026-09-04 · 20:45 CT · S100A
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-750
    C. Saura, S. Antonia · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  62. Abstract 13112026-09-04 · 18:15 CT · S406
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-742 study)
    F. Andre, S. Tolaney, L. Paz-Ares, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  63. Abstract 16062026-09-02 · 18:00 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-702
    L. Paz-Ares, G. Curigliano, C. Saura · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  64. Abstract 11022026-09-01 · 15:30 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-251
    M. Reck, J. Brahmer, F. Andre, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  65. Abstract 18942026-09-01 · 16:00 CT · Hall B1
    MONARCH-133: Verzenio (abemaciclib) 1L in HR+ breast cancer
    A. Spira, C. Saura, H. Borghaei, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  66. Abstract 17572026-09-04 · 15:30 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-465 study)
    C. Robert, M.C. Garassino, S. Tolaney, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  67. Abstract 16092026-09-05 · 19:00 CT · S100A
    MONARCH-764: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    N. Rizvi, C. Robert, H. Rugo, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  68. Abstract 11532026-09-02 · 18:30 CT · E450
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-91
    H. Rugo, N. Rizvi, G. Curigliano, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  69. Abstract 11152026-09-03 · 21:45 CT · Hall B1
    MONALEESA-866: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    P. Schmid, S. Antonia, T. Mok, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  70. Abstract 17072026-09-01 · 15:30 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-578 study)
    S. Peters, L. Paz-Ares, J. Cortes · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  71. Abstract 14662026-09-02 · 18:45 CT · E450
    MONALEESA-112: Kisqali (ribociclib) 2L in HR+ breast cancer
    R. Herbst, L. Paz-Ares, H. Rugo, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  72. Abstract 16062026-09-03 · 15:30 CT · S406
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    R. Herbst, M. Krop, E. Winer, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  73. Abstract 16702026-09-03 · 14:45 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-952
    H. Borghaei, M.C. Garassino · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  74. Abstract 18942026-09-03 · 18:45 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-92
    P. Schmid, R. Herbst, T. Mok, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  75. Abstract 13872026-09-02 · 19:45 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-9 study)
    S. Tolaney, F. Andre, S. Antonia, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  76. Abstract 19492026-09-02 · 14:15 CT · S406
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-772
    H. Borghaei, L. Paz-Ares · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  77. Abstract 10752026-09-02 · 14:15 CT · Hall B1
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-536 study)
    A. Spira, H. Rugo, P. Schmid · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  78. Abstract 17622026-09-02 · 14:30 CT · E450
    Quality of life outcomes with Tecentriq in patients with TNBC
    G. Curigliano, S. Tolaney · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  79. Abstract 16282026-09-04 · 19:00 CT · E450
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-663
    C. Robert, H. Rugo, J. Brahmer, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  80. Abstract 19452026-09-05 · 18:00 CT · Arie Crown Theater
    MONARCH-172: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    T. Mok, J. Brahmer · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  81. Abstract 15962026-09-03 · 19:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-859 study)
    R. Herbst, C. Saura, H. Rugo, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  82. Abstract 19712026-09-04 · 18:45 CT · Hall B1
    MONARCH-555: Verzenio (abemaciclib) 2L in HR+ breast cancer
    G. Curigliano, M.C. Garassino, M. Reck, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  83. Abstract 19352026-09-05 · 16:00 CT · S406
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-658 study)
    R. Herbst, T. Mok, J. Brahmer, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  84. Abstract 12632026-09-01 · 14:30 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-836
    J. Brahmer, S. Antonia · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  85. Abstract 19642026-09-03 · 21:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-171 study)
    H. Rugo, A. Spira, M. Krop, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  86. Abstract 11652026-09-01 · 15:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-22 study)
    H. Borghaei, E. Winer, F. Andre, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  87. Abstract 18892026-09-02 · 19:30 CT · S406
    MONALEESA-79: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    T. Mok, S. Peters, S. Antonia · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  88. Abstract 13422026-09-05 · 18:00 CT · S100A
    OlympiA-472: Lynparza (olaparib) neoadjuvant in HR+ breast cancer
    P. Schmid, G. Curigliano, A. Spira · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  89. Abstract 19322026-09-02 · 20:00 CT · Arie Crown Theater
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-253
    A. Spira, M. Reck, M. Krop, et al. · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  90. Abstract 13562026-09-04 · 21:15 CT · S406
    DESTINY-Breast-72: Enhertu (trastuzumab deruxtecan) neoadjuvant in HR+ breast cancer
    M. Reck, C. Saura, J. Cortes, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  91. Abstract 13342026-09-01 · 21:00 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-173
    P. Schmid, R. Herbst · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  92. Abstract 11452026-09-01 · 19:15 CT · Arie Crown Theater
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    J. Cortes, H. Borghaei · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  93. Abstract 16782026-09-05 · 15:00 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-242 study)
    C. Robert, N. Rizvi, H. Borghaei, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  94. Abstract 17822026-09-05 · 15:45 CT · Hall B1
    MONALEESA-139: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    S. Tolaney, G. Curigliano · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  95. Abstract 12192026-09-05 · 21:00 CT · E450
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-730
    L. Paz-Ares, S. Tolaney, R. Herbst · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  96. Abstract 16402026-09-04 · 15:00 CT · S100A
    DESTINY-Breast-875: Enhertu (trastuzumab deruxtecan) 3L+ in HR+ breast cancer
    P. Schmid, M. Reck, M. Krop, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  97. Abstract 18322026-09-04 · 13:45 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-683 study)
    S. Modi, S. Antonia · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  98. Abstract 16032026-09-02 · 21:00 CT · S100A
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-123
    J. Cortes, A. Spira · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  99. Abstract 19082026-09-02 · 15:45 CT · S406
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-571
    G. Curigliano, H. Rugo, C. Saura · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  100. Abstract 13842026-09-01 · 20:15 CT · Arie Crown Theater
    MONALEESA-278: Kisqali (ribociclib) maintenance in HR+ breast cancer
    M. Reck, R. Herbst, C. Saura, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  101. Abstract 11012026-09-02 · 16:15 CT · Hall B1
    IMpower-879: Tecentriq (atezolizumab) 1L in TNBC
    S. Tolaney, S. Peters · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  102. Abstract 12922026-09-04 · 20:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-227 study)
    R. Herbst, M. Reck, E. Winer, et al. · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  103. Abstract 15672026-09-04 · 16:45 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-28 study)
    P. Schmid, G. Curigliano, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  104. Abstract 19672026-09-02 · 18:45 CT · S100A
    Long-term follow-up of Tecentriq adjuvant for TNBC: IMpower-58
    H. Rugo, M. Reck · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  105. Abstract 12642026-09-05 · 18:00 CT · S100A
    PALOMA-638: Ibrance (palbociclib) maintenance in HR+ breast cancer
    C. Robert, M.C. Garassino, T. Mok, et al. · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  106. Abstract 10512026-09-05 · 13:15 CT · Hall B1
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    L. Paz-Ares, R. Herbst, S. Modi, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  107. Abstract 17662026-09-04 · 21:30 CT · E450
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-115 study)
    P. Schmid, C. Robert, H. Borghaei, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  108. Abstract 16792026-09-03 · 19:00 CT · S406
    MONARCH-821: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    S. Antonia, M. Krop, E. Winer, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  109. Abstract 13612026-09-03 · 18:15 CT · Hall B1
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-354
    M.C. Garassino, T. Mok, E. Winer · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  110. Abstract 19272026-09-01 · 21:30 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-859 study)
    E. Winer, P. Schmid, H. Rugo, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  111. Abstract 11082026-09-02 · 20:15 CT · Arie Crown Theater
    MONALEESA-927: Kisqali (ribociclib) 1L in HR+ breast cancer
    A. Spira, M.C. Garassino, H. Rugo, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  112. Abstract 12442026-09-05 · 16:00 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-154 study)
    A. Spira, J. Cortes, S. Antonia, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  113. Abstract 10632026-09-05 · 20:30 CT · S100A
    DESTINY-Breast-405: Enhertu (trastuzumab deruxtecan) adjuvant in HR+ breast cancer
    S. Modi, M. Reck, J. Cortes · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  114. Abstract 14252026-09-05 · 21:00 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-599 study)
    M. Krop, H. Rugo · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  115. Abstract 15572026-09-01 · 19:00 CT · Arie Crown Theater
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-375
    S. Tolaney, C. Saura · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  116. Abstract 15402026-09-02 · 18:30 CT · Hall B1
    IMpower-431: Tecentriq (atezolizumab) maintenance in TNBC
    F. Andre, M. Krop, R. Herbst, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  117. Abstract 17702026-09-03 · 13:15 CT · Hall B1
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-209
    J. Brahmer, H. Rugo, G. Curigliano, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  118. Abstract 18042026-09-03 · 16:15 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-241
    J. Cortes, S. Tolaney, C. Saura · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  119. Abstract 18442026-09-05 · 21:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-368 study)
    S. Antonia, A. Spira, F. Andre, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  120. Abstract 15982026-09-01 · 20:30 CT · Hall B1
    OlympiA-553: Lynparza (olaparib) 3L+ in HR+ breast cancer
    H. Borghaei, R. Herbst, F. Andre, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  121. Abstract 14742026-09-03 · 16:30 CT · S406
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-786
    J. Cortes, A. Spira, P. Schmid, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  122. Abstract 18982026-09-04 · 14:30 CT · E450
    Long-term follow-up of Tecentriq 3L+ for TNBC: IMpower-518
    H. Borghaei, S. Peters · University of Chicago
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  123. Abstract 17622026-09-02 · 19:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-913 study)
    S. Peters, M. Reck · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  124. Abstract 18772026-09-03 · 19:00 CT · S100A
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-266
    S. Antonia, M. Krop, E. Winer, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  125. Abstract 13102026-09-03 · 20:00 CT · Arie Crown Theater
    ASCENT-707: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    A. Spira, C. Robert, C. Saura, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  126. Abstract 12342026-09-03 · 14:30 CT · S100A
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-271
    S. Antonia, R. Herbst, M.C. Garassino, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  127. Abstract 10672026-09-04 · 16:00 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-823
    A. Spira, R. Herbst, E. Winer, et al. · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  128. Abstract 12212026-09-05 · 19:45 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-437
    C. Robert, S. Tolaney, M. Krop, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  129. Abstract 12682026-09-04 · 16:45 CT · Arie Crown Theater
    PALOMA-251: Ibrance (palbociclib) 2L in HR+ breast cancer
    A. Spira, G. Curigliano · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  130. Abstract 18872026-09-05 · 14:30 CT · E450
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-364
    L. Paz-Ares, M. Krop, M. Reck, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  131. Abstract 15572026-09-01 · 16:15 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-261
    M.C. Garassino, G. Curigliano, P. Schmid, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  132. Abstract 17872026-09-04 · 20:15 CT · Hall B1
    Long-term follow-up of Tecentriq adjuvant for TNBC: IMpower-103
    C. Saura, G. Curigliano · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  133. Abstract 17182026-09-02 · 21:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-713 study)
    R. Herbst, S. Antonia, F. Andre, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  134. Abstract 10942026-09-01 · 19:00 CT · S100A
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-612 study)
    H. Borghaei, P. Schmid, E. Winer, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  135. Abstract 11852026-09-05 · 15:15 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-594
    S. Modi, M. Reck, R. Herbst, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  136. Abstract 16592026-09-04 · 13:15 CT · E450
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-875
    J. Brahmer, H. Rugo, L. Paz-Ares, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  137. Abstract 15842026-09-01 · 13:45 CT · S406
    MONARCH-479: Verzenio (abemaciclib) 2L in HR+ breast cancer
    E. Winer, C. Robert, R. Herbst · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  138. Abstract 16282026-09-05 · 19:30 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-861
    M. Krop, J. Cortes, S. Peters, et al. · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  139. Abstract 19382026-09-01 · 18:30 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-477
    S. Modi, G. Curigliano · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  140. Abstract 16182026-09-01 · 20:15 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-33
    G. Curigliano, C. Robert, H. Rugo, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  141. Abstract 16532026-09-01 · 18:45 CT · Hall B1
    MONALEESA-766: Kisqali (ribociclib) maintenance in HR+ breast cancer
    A. Spira, P. Schmid, S. Tolaney · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  142. Abstract 18052026-09-04 · 16:15 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-248
    A. Spira, C. Saura, N. Rizvi, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  143. Abstract 14262026-09-04 · 15:45 CT · Hall B1
    PALOMA-470: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    R. Herbst, S. Peters · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  144. Abstract 13582026-09-05 · 18:45 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-203
    M. Krop, L. Paz-Ares · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  145. Abstract 19112026-09-02 · 21:30 CT · S406
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-62
    G. Curigliano, M. Reck · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  146. Abstract 14912026-09-03 · 13:30 CT · E450
    PALOMA-514: Ibrance (palbociclib) 2L in HR+ breast cancer
    S. Antonia, L. Paz-Ares, M. Reck · Cleveland Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  147. Abstract 14482026-09-01 · 15:45 CT · E450
    Long-term follow-up of Tecentriq neoadjuvant for TNBC: IMpower-97
    H. Rugo, N. Rizvi, S. Modi, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  148. Abstract 16662026-09-03 · 18:00 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-613 study)
    C. Saura, M.C. Garassino, N. Rizvi, et al. · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  149. Abstract 13312026-09-03 · 21:15 CT · Hall B1
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-836
    M.C. Garassino, C. Saura, S. Tolaney · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  150. Abstract 19952026-09-02 · 18:00 CT · Hall B1
    MONALEESA-27: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    S. Antonia, S. Tolaney, S. Modi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  151. Abstract 17882026-09-05 · 19:45 CT · E450
    ASCENT-337: Trodelvy (sacituzumab govitecan) 2L in TNBC
    F. Andre, H. Rugo, M. Reck · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  152. Abstract 12082026-09-03 · 19:30 CT · Arie Crown Theater
    Long-term follow-up of Enhertu 1L for HR+ breast cancer: DESTINY-Breast-638
    R. Herbst, C. Robert, M.C. Garassino · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  153. Abstract 13012026-09-04 · 16:15 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-682 study)
    F. Andre, A. Spira, S. Tolaney, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  154. Abstract 16942026-09-05 · 20:45 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-601 study)
    S. Modi, L. Paz-Ares, H. Rugo, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  155. Abstract 12632026-09-04 · 21:15 CT · S406
    MONARCH-613: Verzenio (abemaciclib) 1L in HR+ breast cancer
    S. Antonia, N. Rizvi, L. Paz-Ares, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  156. Abstract 16842026-09-05 · 14:15 CT · S100A
    Long-term follow-up of Lynparza 1L for HR+ breast cancer: OlympiA-338
    M. Krop, J. Cortes, A. Spira, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  157. Abstract 19082026-09-02 · 15:15 CT · S100A
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-536
    A. Spira, T. Mok, H. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  158. Abstract 16762026-09-05 · 18:45 CT · E450
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-256 study)
    S. Peters, L. Paz-Ares, M.C. Garassino · Stanford Cancer Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  159. Abstract 18242026-09-01 · 16:00 CT · E450
    ASCENT-551: Trodelvy (sacituzumab govitecan) neoadjuvant in TNBC
    R. Herbst, S. Antonia, N. Rizvi · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  160. Abstract 19482026-09-01 · 20:45 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-218
    M.C. Garassino, S. Modi, J. Brahmer, et al. · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  161. Abstract 13522026-09-04 · 13:30 CT · S100A
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-491
    A. Spira, S. Peters, S. Antonia · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.